Reuters logo
BRIEF-BBI Life Sciences says Sangon Health Sci-Tech entered into investment agreement with shareholders of Tianjin Hengjia Boitech Development
March 6, 2017 / 9:02 AM / in 8 months

BRIEF-BBI Life Sciences says Sangon Health Sci-Tech entered into investment agreement with shareholders of Tianjin Hengjia Boitech Development

March 6 (Reuters) - Bbi Life Sciences Corp-

* VIE company of company entered into an investment agreement with shareholders of Tianjin Hengjia Boitech Development Company Limited

* Sangon Health will obtain 34% equity interest Of Tianjin Hengjia by investment, with increase in capital amount of rmb6 million. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below